Tailoring Therapy for Achalasia

Area of Science:

• Gastroenterology
• Esophageal Motility Disorders

Background:

• Achalasia is a rare esophageal motility disorder characterized by impaired lower esophageal sphincter (LES) opening and aperistalsis.
• While achalasia is incurable, effective long-term symptom relief can be achieved through treatments that reduce LES obstruction.

Purpose of the Study:

• To review current achalasia treatments.
• To discuss tailoring therapy based on individual patient characteristics and achalasia type.

Main Methods:

• Review of existing scientific literature on achalasia treatments.
• Comparative analysis of efficacy, morbidity, and suitability of different therapeutic options.

Main Results:

• Drug therapy (e.g., botulinum toxin A) is best for elderly patients with limited life expectancy.
• Pneumatic dilation and surgical myotomy are equally effective for achalasia types I and II; pneumatic dilation is less morbid and cheaper, while myotomy is effective across all groups.
• Laparoscopic Heller myotomy with fundoplication is preferred for megaesophagus, diverticulum, or hiatal hernia.
• Peroral endoscopic myotomy is the primary choice for type III achalasia, despite requiring advanced skills and carrying a high risk of gastroesophageal reflux disease.

Conclusions:

• Multiple effective treatment options exist for achalasia, allowing for personalized therapeutic strategies.
• Treatment selection should consider achalasia type, patient age, comorbidities, and specific anatomical factors.